| Literature DB >> 26922775 |
Jean-Baptiste Fraison1, Arsène Mekinian2, Eric Grignano3, Jean-Emmanuel Kahn4, Jean-Benoit Arlet5, Olivier Decaux6, Guillaume Denis7, Anne-Laure Buchdahl8, Mohamed Omouri9, Gwenola Maigne10, Achille Aouba10, Nathalie Leon11, Sabine Berthier12, Eric Liozon13, Sophie Park14, Claude Gardin15, Olivier Lortholary16, Julien Rossignol3, Pierre Fenaux17, Olivier Fain2, Thorsten Braun15.
Abstract
This retrospective study describes efficacy of Azacitidine on autoimmune disorders (AID) associated with MDS/CMML in 22 patients. Response of AID to Azacitidine was observed in 19 patients (86%). Reduction or discontinuation of steroids and/or immunosuppressive therapy (IST) was possible in 16 cases (73%). Hematologic response was seen in 55% of the patients. MDS/CMML and AID evolution was concordant in 13 cases (59%): both favorable (n=11), both unfavorable (n=2), but AID improved while MDS/CMML worsened (n=8) and vice versa (n=1). Azacitidine frequently seems effective in controlling steroid-dependent AID associated with MDS/CMML, but prospective studies are necessary to confirm those findings.Entities:
Keywords: Auto immune disorders; Azacitidine; Myelodysplastic syndromes
Mesh：
Substances：
Year: 2016 PMID： 26922775 DOI： 10.1016/j.leukres.2016.02.005
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156